# Catalyst Biosciences (CBIO) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/CBIO
## Company Profile
- Ticker: CBIO
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 13.57 USD
- Market cap: 468909899.125 USD
- Last updated: 2026-10-06
## Business Overview
Catalyst Biosciences was a biotechnology company focused on engineered proteins for hemostasis, complement, and related inflammatory biology before becoming a historical ticker. Its story was built around protein-engineering approaches to difficult disease pathways.
## Why The Stock Is Moving

As of Oct 6, 2026, CBIO closed down 2.65% at $13.57. No new same-company headline was identified in the current news window.

## Geographic Base

Catalyst Biosciences was headquartered in the United States and listed on NASDAQ. It sat in specialty biotech with a protein-engineering focus.

## Business Model

The company depended on translational data, strategic direction, and financing while working through a narrow pipeline. Investors historically watched whether the platform could create durable value across multiple programs.

## Landscape Position

Catalyst Biosciences belongs to the historical engineered-protein biotech bucket. Its stock was highly sensitive to strategic changes and the viability of its platform thesis.

## Future Catalysts

- Catalyst Biosciences is largely a legacy / closeout story, with catalysts limited to any remaining strategic update. There is no active standalone growth story left.

## Recent News
- 2026-09-03 11:00 EST — [Gyre Therapeutics to Participate in Upcoming September Investor Conferences](https://biopharmsignal.com/news/CBIO/gyre-therapeutics-to-participate-in-upcoming-september-investor-conferences-df9c0225) — Source: Catalyst Biosciences
- 2026-08-07 11:00 EST — [Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update](https://biopharmsignal.com/news/CBIO/gyre-therapeutics-reports-second-quarter-2026-and-year-to-date-financial-results-1f32e996) — Source: Catalyst Biosciences
- 2026-07-16 20:05 EST — [Gyre Therapeutics Appoints Three New Members to its Board of Directors](https://biopharmsignal.com/news/CBIO/gyre-therapeutics-appoints-three-new-members-to-its-board-of-directors-baf9de29) — Source: Catalyst Biosciences
- 2026-05-12 20:06 EST — [Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment](https://biopharmsignal.com/news/CBIO/gyre-therapeutics-announces-nmpa-acceptance-of-new-drug-application-for-f351-hydronidone-for-chb-induced-liver-fibrosis-treatment) — Source: Catalyst Biosciences
- 2026-05-07 10:00 EST — [Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update](https://biopharmsignal.com/news/CBIO/gyre-therapeutics-reports-first-quarter-2026-results-and-provides-business-update) — Source: Catalyst Biosciences